{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "genotype",
      "pathogenic",
      "vaccine",
      "variants"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34856855",
  "DateCompleted": {
    "Year": "2022",
    "Month": "03",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "12",
        "Day": "02"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1080/21645515.2021.1997487"
    ],
    "Journal": {
      "ISSN": "2164-554X",
      "JournalIssue": {
        "Volume": "17",
        "Issue": "12",
        "PubDate": {
          "Year": "2021",
          "Month": "Dec",
          "Day": "02"
        }
      },
      "Title": "Human vaccines & immunotherapeutics",
      "ISOAbbreviation": "Hum Vaccin Immunother"
    },
    "ArticleTitle": "Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine.",
    "Pagination": {
      "StartPage": "5145",
      "EndPage": "5147",
      "MedlinePgn": "5145-5147"
    },
    "Abstract": {
      "AbstractText": [
        "The circulating variants of SARS-CoV-2 pose a threat to the public health response worldwide, especially in the case of developing countries, lacking vaccines and having compromised health-care facilities. This article highlights several recent studies conducted to determine the efficacy of COVID-19 vaccines against variants of concern. These studies comprise clinical trials and neutralization assay-based studies conducted on messenger RNA (mRNA), recombinant, viral vector-based, and inactivated vaccines."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India."
          }
        ],
        "LastName": "Singh",
        "ForeName": "Abhay",
        "Initials": "A"
      },
      {
        "Identifier": [
          "0000-0002-8526-6013"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India."
          }
        ],
        "LastName": "Kumar",
        "ForeName": "Sachin",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Hum Vaccin Immunother",
    "NlmUniqueID": "101572652",
    "ISSNLinking": "2164-5515"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Vaccines, Inactivated"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genotype"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccines, Inactivated"
    }
  ],
  "CoiStatement": "No potential conflict of interest was reported by the author(s)."
}